AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12204931 — intervention group
Group type: COMPARATOR
Intervention: Dysphoria (Hospital Anxiety and Depression scale)
Number of subjects: 114
Study 9842172 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered postpartum care (FCPPC)
Number of subjects: 0
Study 9842172 — intervention group
Group type: COMPARATOR
Intervention: Traditional postpartum care (TPPC)
Number of subjects: 0
Study 8082374 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature injectate using an external thermistor
Number of subjects: 20
Study 8082374 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature injectate using an internal RA thermistor
Number of subjects: 20
Study 8082374 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced injectate using an external thermistor
Number of subjects: 20
Study 8082374 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced injectate using an internal RA thermistor
Number of subjects: 20
Study 2698591 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor by stripping of membranes and i.v. oxytocin infusion, with artificial rupture of membranes when the cervical opening was 3 cm or more in diameter.
Number of subjects: 188
Study 2698591 — intervention group
Group type: COMPARATOR
Intervention: Close monitoring without induction except when indicated for medical reasons.
Number of subjects: 188
Study 338079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (10 g during the first 2 1/2 days)
Number of subjects: 482
Study 338079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 31294648 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed condition (participants told they were being evaluated)
Number of subjects: 0
Study 31294648 — intervention group
Group type: COMPARATOR
Intervention: Unobserved condition (participants performed tasks with no mention of observation or evaluation)
Number of subjects: 0
Study 31551192 — intervention group
Group type: EXPERIMENTAL
Intervention: CircRNA expression in vaginal epithelial tissue from women with LDs
Number of subjects: 2
Study 31551192 — intervention group
Group type: COMPARATOR
Intervention: CircRNA expression in vaginal epithelial tissue from normal control groups
Number of subjects: 2
Study 27745812 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 (120 μg)
Number of subjects: 210
Study 27745812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 25996793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (PK)
Number of subjects: 92
Study 25996793 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 92
Study 22801243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg
Number of subjects: 452
Study 22801243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 21300305 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Home Monitoring (AHM)
Number of subjects: 188
Study 21300305 — intervention group
Group type: COMPARATOR
Intervention: Standard-Care Group (NAHM)
Number of subjects: 188
Study 18308500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print intervention
Number of subjects: 140
Study 18308500 — intervention group
Group type: COMPARATOR
Intervention: Nontailored print intervention
Number of subjects: 140
Study 16053850 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (15 microg/ml)
Number of subjects: 40
Study 16053850 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (12.5 microg/ml)
Number of subjects: 40
Study 11943931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 62
Study 11943931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thalidomide)
Number of subjects: 62
Study 11943931 — intervention group
Group type: EXPERIMENTAL
Intervention: APC resistance (regardless of thalidomide)
Number of subjects: 62
Study 11943931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide with APC resistance
Number of subjects: 62
Study 11943931 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal APC response without thalidomide
Number of subjects: 62
Study 10065788 — intervention group
Group type: EXPERIMENTAL
Intervention: MH61 monoclonal antibody
Number of subjects: 39
Study 10065788 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-color fluorescence staining with FITC-PSA and anti-CD46 monoclonal antibody
Number of subjects: 39
Study 8543350 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 388
Study 8543350 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 388
Study 2207824 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.2 mg/kg)
Number of subjects: 28
Study 2207824 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 28
Study 2207824 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 28
Study 6108729 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 0
Study 6108729 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 29121415 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily until progressive disease, death, or unacceptable toxicity
Number of subjects: 20
Study 27652249 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF with DBM
Number of subjects: 36
Study 27652249 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF alone
Number of subjects: 36
Study 27652249 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 36
Study 24975110 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention with a telephone booster after 6 weeks and a manual-guided intervention for caregivers
Number of subjects: 312
Study 24975110 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 312
Study 23536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg/day for 4 weeks, then randomized to 125 mg/day (Group 1) or 250 mg/day (Group 2) for 12 weeks.
Number of subjects: 35
Study 23536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg/day (Group 1)
Number of subjects: 35
Study 23536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg/day (Group 2)
Number of subjects: 35
Study 23536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (both groups)
Number of subjects: 35
Study 23536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (Group 2)
Number of subjects: 35
Study 20967979 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antibacterial treatment consisting of bladder ionophoresis, vaginal exposure to estrogens, and vibromagnetic action of RECTOMASSAGER attachment and AMUS‐01‐INTRAMAG device
Number of subjects: 68
Study 20967979 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment
Number of subjects: 68
Study 18687385 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate monotherapy for 6 weeks
Number of subjects: 10
Study 18687385 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 16184836 — intervention group
Group type: EXPERIMENTAL
Intervention: Behcet's disease patients
Number of subjects: 12
Study 12526235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal gas insufflation (flow rate 6 L/min)
Number of subjects: 14
Study 12526235 — intervention group
Group type: COMPARATOR
Intervention: No flow (control)
Number of subjects: 14
Study 11090767 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulation intensity (3x perception threshold)
Number of subjects: 14
Study 11090767 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation intensity (1.5x pain threshold)
Number of subjects: 14
Study 9221412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D time of flight (TOF) MRA
Number of subjects: 54
Study 9221412 — intervention group
Group type: COMPARATOR
Intervention: 3D phase contrast (PC) MRA
Number of subjects: 54
Study 8102428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.4 mg/kg every 12 h for 2 days)
Number of subjects: 115
Study 8102428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 8102428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 115
Study 3463350 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of Abstinence (AB)
Number of subjects: 70
Study 3463350 — intervention group
Group type: COMPARATOR
Intervention: Controlled Drinking (CD)
Number of subjects: 70
Study 3463350 — intervention group
Group type: COMPARATOR
Intervention: Lighter clients (AB vs CD)
Number of subjects: 70
Study 3463350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier clients (CD)
Number of subjects: 70
Study 3463350 — intervention group
Group type: EXPERIMENTAL
Intervention: First 3 weeks of treatment (abstinent or not)
Number of subjects: 70
Study 3463350 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining 3 weeks of treatment (moderate drinker or not)
Number of subjects: 70
Study 31982585 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video group
Number of subjects: 24
Study 31982585 — intervention group
Group type: COMPARATOR
Intervention: Traditional residency training group
Number of subjects: 24
Study 29379278 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (7 mL PRP solution)
Number of subjects: 42
Study 29379278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (PRL) injection (7 mL 25% dextrose)
Number of subjects: 42
Study 27893109 — intervention group
Group type: EXPERIMENTAL
Intervention: SYL1001 1.125% once daily
Number of subjects: 156
Study 27893109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 24623027 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Education treatment
Number of subjects: 226
Study 24623027 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized coping skills education
Number of subjects: 226
Study 22555622 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg per day)
Number of subjects: 8
Study 22555622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19729266 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone continuing care (TCC)
Number of subjects: 0
Study 19729266 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone continuing care (TCC) among lower severity (LS) participants
Number of subjects: 0
Study 19729266 — intervention group
Group type: COMPARATOR
Intervention: Usual continuing care (UCC)
Number of subjects: 0
Study 19729266 — intervention group
Group type: COMPARATOR
Intervention: Usual continuing care (UCC) among lower severity (LS) participants
Number of subjects: 0
Study 18567918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily for 14 days
Number of subjects: 25
Study 18567918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16266356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg
Number of subjects: 491
Study 16266356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg
Number of subjects: 491
Study 16266356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg and 40 mg
Number of subjects: 491
Study 16266356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 12087719 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutoxim
Number of subjects: 42
Study 10795950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude behavioral incentives ($5/day vouchers for 7 days)
Number of subjects: 0
Study 10795950 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentives)
Number of subjects: 0
Study 8871884 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (10 day course, oral)
Number of subjects: 11
Study 8871884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1373429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy (2 cycles)
Number of subjects: 114
Study 1373429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with radiosensitizing agent (3 cycles)
Number of subjects: 114
Study 4063689 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐Z‐CAT (barium sulphate)
Number of subjects: 111
Study 4063689 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate (Gastrografin)
Number of subjects: 111
Study 29395372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (whey protein, vitamin D, and E)
Number of subjects: 60
Study 29903551 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically adaptive chemoradiation (85 Gy in 30 fractions)
Number of subjects: 78
Study 29903551 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiation treatment (60 Gy in 30 fractions)
Number of subjects: 78
Study 29903551 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically adaptive chemoradiation
Number of subjects: 78
Study 29903551 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiation
Number of subjects: 78
Study 27776036 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 19
Study 27776036 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 19
Study 24025633 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (9.7 to 10.7 mg/d)
Number of subjects: 193
Study 24025633 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, 1.3 to 1.4 mg/d)
Number of subjects: 193
Study 24025633 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 193
Study 20080256 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of bupivacaine
Number of subjects: 70
Study 20080256 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 70
Study 19751371 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg twice daily
Number of subjects: 179
Study 19751371 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg once daily
Number of subjects: 179
Study 19751371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 16895945 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate computed tomography
Number of subjects: 2602
Study 16895945 — intervention group
Group type: COMPARATOR
Intervention: Admission for observation
Number of subjects: 2602
Study 15125339 — intervention group
Group type: EXPERIMENTAL
Intervention: Holdex de Vacuette (H)
Number of subjects: 512
Study 15125339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacutainer (V)
Number of subjects: 512
Study 15125339 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe (J)
Number of subjects: 512
Study 15125339 — intervention group
Group type: COMPARATOR
Intervention: All samples analyzed
Number of subjects: 512
Study 11439207 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART (continuous hyperfractionated accelerated radiotherapy)
Number of subjects: 918
Study 11439207 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 918
Study 11439207 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 918
Study 9383928 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention (home visits from a lay home visitor for 1 year)
Number of subjects: 0
Study 9383928 — intervention group
Group type: COMPARATOR
Intervention: Standard services in a multidisciplinary growth and nutrition clinic (control group)
Number of subjects: 0
Study 7524908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (Ig) at a dose of 500 mg/kg every 2 weeks for the first 100 days post-BMT
Number of subjects: 11
Study 7524908 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of anti-HCV antibodies
Number of subjects: 11
Study 7524908 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening of donors with sensitive tests
Number of subjects: 11
Study 3365327 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive administration of placebo
Number of subjects: 0
Study 3365327 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind administration of placebo
Number of subjects: 0
Study 3365327 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effects on motor performance
Number of subjects: 0
Study 29618329 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital exercise prescription tool with standard lifestyle consultation for 3 months
Number of subjects: 0
Study 29618329 — intervention group
Group type: COMPARATOR
Intervention: Standard usual-cardio-care lifestyle counselling for 3 months
Number of subjects: 0
Study 26706398 — intervention group
Group type: EXPERIMENTAL
Intervention: SEAD program (2-week curriculum with operating room observerships, simulation workshops, and career discussions)
Number of subjects: 36
Study 26706398 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading the program's instructional manual)
Number of subjects: 36
Study 26706398 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SEAD and control)
Number of subjects: 36
Study 26670153 — intervention group
Group type: EXPERIMENTAL
Intervention: More behaviours for escaping from a house fire group
Number of subjects: 1112
Study 26670153 — intervention group
Group type: COMPARATOR
Intervention: Fewer behaviours for escaping from a house fire group
Number of subjects: 1112
Study 22960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent motor control
Number of subjects: 21
Study 22960153 — intervention group
Group type: COMPARATOR
Intervention: Free-hand motor control
Number of subjects: 21
Study 20639738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg + TENS
Number of subjects: 30
Study 20639738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg + TENS
Number of subjects: 30
Study 20639738 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 300 mg + TENS placebo
Number of subjects: 30
Study 20639738 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 600 mg + TENS placebo
Number of subjects: 30
Study 20639738 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 18615004 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 5895
Study 18615004 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR
Number of subjects: 5895
Study 20806385 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative 1,550 nm fractional laser therapy (FLT) - 4-5 sessions at 15 mJ/microbeam, 14-20% coverage
Number of subjects: 29
Study 20806385 — intervention group
Group type: COMPARATOR
Intervention: Triple topical therapy (TTT) - hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream, applied once daily for 15 weeks
Number of subjects: 29
Study 15542574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (end‐tidal Po(2) = 50 Torr) for 25 min (Study A)
Number of subjects: 19
Study 15542574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (end‐tidal Po(2) = 50 Torr) for 105 min (Study B)
Number of subjects: 19
Study 15542574 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic euoxia (end‐tidal Po(2) = 100 Torr) for 5 min (Study A)
Number of subjects: 19
Study 15542574 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic euoxia (end‐tidal Po(2) = 100 Torr) for 10 min (Study B)
Number of subjects: 19
Study 12187632 — intervention group
Group type: EXPERIMENTAL
Intervention: Metropolitan Primary Angioplasty Registry
Number of subjects: 0
Study 9832694 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery grafts
Number of subjects: 68
Study 9832694 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parietal irregularities
Number of subjects: 68
Study 9832694 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin challenge
Number of subjects: 68
Study 9832694 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel antagonists therapy
Number of subjects: 68
Study 9832694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative severity of target-vessel stenosis
Number of subjects: 68
Study 7975696 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (ASPTV)
Number of subjects: 100
Study 7975696 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 100
Study 2730323 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for one day (n = 23)
Number of subjects: 64
Study 2730323 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for four days (n = 27)
Number of subjects: 64
Study 2730323 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for four days (n = 14)
Number of subjects: 64
Study 12219850 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with strong merit endorsement
Number of subjects: 0
Study 12219850 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with preexisting perceptions of workplace discrimination
Number of subjects: 0
Study 12219850 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally induced perceptions of discrimination
Number of subjects: 0
Study 31636172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2658
Study 31636172 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 2658
Study 31636172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2658
Study 31636172 — intervention group
Group type: COMPARATOR
Intervention: Metformin or placebo
Number of subjects: 2658
Study 29789414 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized fitting device using 3D scanning solution
Number of subjects: 20
Study 29789414 — intervention group
Group type: COMPARATOR
Intervention: Control (no fitting device)
Number of subjects: 20
Study 27284581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracaine DS Forte (treatment group)
Number of subjects: 50
Study 27284581 — intervention group
Group type: COMPARATOR
Intervention: Ultracaine DS (control group)
Number of subjects: 50
Study 23881570 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (20 words once)
Number of subjects: 3
Study 23881570 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (20 words three times)
Number of subjects: 3